Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.51 |
| ▸ | FLT1 | P17948 | 8/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | CDK8 | P49336 | 2/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2888120 | 0.94 | BRAF (0.53) | KDRFLT1EPHB4BRAFBLM | |
| SCHEMBL14567026 | 0.92 | FLT1 (0.43) | KDRFLT1EPHB4BRAFCDK8 | |
| SCHEMBL10330906 | 0.86 | CCNC (0.43) | KDRFLT1BRAFCDK8CCNC | |
| SCHEMBL10330874 | 0.84 | NR1I2 (0.43) | KDRFLT1BRAFCDK8CCNC | |
| SCHEMBL2886220 | 0.79 | KDR (0.45) | KDREPHB4BRAF | |
| SCHEMBL5592683 | 0.76 | EPHB4 (0.53) | KDRFLT1EPHB4BRAF | |
| SCHEMBL5636147 | 0.75 | KDR (0.51) | KDRFLT1EPHB4BRAFCDK8 | |
| SCHEMBL2887786 | 0.74 | KDR (0.43) | KDREPHB4 | |
| SCHEMBL4338219 | 0.73 | EPHB4 (0.55) | KDRFLT1EPHB4BRAFCDK8 | |
| SCHEMBL5611430 | 0.71 | BRAF (0.75) | KDRFLT1EPHB4BRAFBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222421-B2 | Certain substituted ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. (US) | 2012-07-17 | — | — | US | claimed |
| US-20100286190-A1 | CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. | 2010-11-11 | — | — | US | claimed |
| WO-2007024294-A2 | CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | claimed |
| US-20060270702-A1 | Certain substituted ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-11-30 | — | — | US | claimed |
| US-8222421-B2 | Certain substituted ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222421-B2 | Certain substituted ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20100286190-A1 | CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286190-A1 | CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. | 2010-11-11 | — | — | US | disclosed |
| US-7777040-B2 | Certain substituted ureas, as modulators of kinase activity | CGI PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7777040-B2 | Certain substituted ureas, as modulators of kinase activity | CGI PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7777040-B2 | Certain substituted ureas, as modulators of kinase activity | CGI PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| WO-2007024294-A2 | CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007024294-A2 | CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20060270702-A1 | Certain substituted ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270702-A1 | Certain substituted ureas, as modulators of kinase activity | UCK2, CHUK, TK1 | KDR 47/4885FLT1 11/4885EPHB4 2792/4885 |
| US-20100286190-A1 | CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY | UCK2, CHUK, TK1 | KDR 47/4885FLT1 11/4885EPHB4 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.